Lotvin Alan
Known title: EVP&President-PharmacyServicesCIK: 0001472795
Associated companies
Transaction History
| CVS | ▼ Sell | Open Market | 22,541 | $2.3M | 8/4/2022 | View on chart |
| CVS | ▲ Buy | Option Exercise | 22,541 | $1.4M | 8/4/2022 | View on chart |
| CVS | ▼ Sell | Open Market | 50,501 | $4.9M | 8/3/2022 | View on chart |
| CVS | ▲ Buy | Option Exercise | 70,398 | $4.1M | 8/3/2022 | View on chart |
| CVS | ▲ Buy | Option Exercise | 50,501 | $2.7M | 8/3/2022 | View on chart |
| CVS | ▼ Sell | Open Market | 70,398 | $6.9M | 8/3/2022 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 38,129 | $3.9M | 4/1/2022 | View on chart |
| CVS | ▲ Buy | Grant | 85,971 | $0 | 2/21/2022 | View on chart |
| CVS | ▲ Buy | Option Exercise | 21,386 | $2.2M | 2/1/2022 | View on chart |
| CVS | ▼ Sell | Open Market | 21,386 | $2.3M | 2/1/2022 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 200 | $18K | 12/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status
CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.